NetWitness Launches Comprehensive XDR Offerings for Next Generation Security
7.6.2022 19:00:00 EEST | Business Wire | Press release
NetWitness, a globally trusted provider of cybersecurity technologies and incident response, today announced NetWitness XDR, a family of products and capabilities delivering comprehensive detection and response on premise, in the cloud or as a hybrid of the two. This new offering and product architecture delivers the full range of deployment options enterprises seek today to meet their unique cybersecurity needs and use cases.
NetWitness XDR delivers a robust set of capabilities enabling extended detection and response (XDR) and helping customers stay ahead of the most sophisticated cyber threats. These include:
- Unified collection, data, and visibility across multiple security layers
- Automatic enrichment of data using any technical or business source
- A wide toolset of detection technologies including, but not limited to, advanced behavioral analysis
- External and internal threat intelligence to identify known security risks and threat actors
- Truly insightful context, visualization, and investigation tools
- Threat hunting tools and methodologies to identify previously unknown threats
- Highly repeatable and measurable incident investigation and response processes
- A strong array of both automated and human response options
“NetWitness has enjoyed the trust of some of the world’s most security sensitive organizations because of its unique ability to monitor the entire attack surface across the network, endpoint, cloud, IoT, logs and more,” said CEO of RSA and NetWitness, Rohit Ghai. “We have been delivering XDR capability to the market for several years and today we are delighted to announce new innovations in the platform and reintroduce it to the market as NetWitness XDR.”
Under this new model, NetWitness XDR will be comprised of three main product lines that showcase its uniquely powerful support for all XDR use cases. NetWitness Platform XDR 12 is the newest major release of NetWitness Platform. This technology stack, typically deployed as customer-managed software or hosted by MSSPs, has been enhanced to focus on detection capabilities that identify threats faster and decrease their impact. The company’s new cloud-native SaaS version will be known as NetWitness Vision XDR and is currently in design preview. The third product line, NetWitness XDR Cloud Services, is a set of optional SaaS applications that take advantage of the cloud’s inherent elastic nature to deliver flexible and cost-effective components which can be used to augment either Platform XDR or Vision XDR.
“Our network-forward approach allows us to stand out in this emerging space and highlights NetWitness XDR’s ability to detect across customers’ growing number of systems and devices,” said Director of Product Management and Research, Kevin Bowers. “We are embracing the belief that the best XDR must be consumable on prem, in the cloud, and hybrid.”
Developed initially in 1996, NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and tools to detect and respond to them. Since then, the technology has continuously evolved and been innovated to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response that drive its threat intelligence and security orchestration platform, NetWitness Orchestrator. With its long history and global footprint, NetWitness XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.
NetWitness XDR will host demonstrations at its booth at RSA Conference this year for Platform XDR and Vision XDR.
To learn more, visit www.netwitness.com.
ABOUT NetWitness
NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com.
©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005204/en/
Contact information
SHIFT Communications
netwitness@shiftcomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom